Drug-release kinetics characterization of gentamicin from TiO2 nanotubes and its antibacterial activity in vitro
FENG Mingguang1,LIU Zhongtang2, WANG Liqiang3, XU Li1, YANG Haitao1, WANG Jian1, WANG Haiyang1,and QING Shixin1
1.Department of Orthopedics, Shanghai Municipal Corps Hospital Chinese People’s Armed Police Force, Shanghai 201103, China; 2.Department of Orthopedics, the Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai 200233,China; 3.College of Materials Science and Engineering, Shanghai Jiaotong University, Shanghai 200240, China
Abstract:Objective To determine the release kinetics of gentamicin from the TiO2 nanotubes(TNS-G), and to detect its antibacterial activity in vitro. Methods TiO2 nanotubes (NTS) were fabricated on the titanium surface by electrochemical anodization. These nanotubes were loaded with gentamicin using a lyophilization method and vacuum drying, and its pharmacokinetics was detected in phosphate buffer. Staphylococcus aureus was used to study the antibacterial properties of the NTS-G. There were three study groups: the commercially pure titanium(Cp-Ti)group, the NTS group, and the NTS-G group.We compared the antibacterial efficacy with each other by bacterial adhesion and colony counting in bacterial culture. Results Drug release of NTS-G could be divided into two parts: initial burst release and relatively slow release.The fast initial concentration was 51.50 μg/ml , and 73.13 μg/ml at the 6 th hours. Most of load gentamicin was released within approximately 9 hours.In the second phase, different drug release kinetics were observed, with very slow and linearly increasing cumulative release over a period of 90 h. The drug concentration was maintained at about 89.10 μg/ml. We found that NTS-G could significantly inhibit bacterial adhesion and bioflm formation, compared with Cp-Ti or NTS, (P<0.05). Conclusions Titanium dioxide nanotubes loaded with antibiotics can deliver a high concentration of antibiotics locally at a specifc site, thereby providing a new strategy to prevent implant-associated infections.
冯明光,刘忠堂,王立强,徐丽,杨海涛,王健,王海洋,秦士新. 钛表面TiO2纳米管抗菌覆膜药物释放动力学表征及其抗菌活性体外研究[J]. 武警医学, 2015, 26(11): 1129-1133.
FENG Mingguang,LIU Zhongtang, WANG Liqiang, XU Li, YANG Haitao, WANG Jian, WANG Haiyang,and QING Shixin. Drug-release kinetics characterization of gentamicin from TiO2 nanotubes and its antibacterial activity in vitro. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(11): 1129-1133.
Gulati K, Aw M S, Findlay D, et al. Local drug delivery to the bone bydrug-releasing implants: perspectives of nano-engineered titania nanotube arrays[J].TherDeliv,2012,3(7):857-873.
[1]
Zhang Hangzhou, Yu Sun, Ang Tian, et al. Improved antibacterial activity and biocompatibility on vancomycin-loaded TiO2 nanotubes: in vivo and in vitro studies[J].International Journal of Nanomedicine, 2013(8):4379-4389.
[12]
Berger R A, Jacobs J J, Quigley L R, et al. Primary cementlessacetabular reconstruction in patients younger than 50 years old. 7- to 11-year results[J]. ClinOrthopRelat Res, 1997,(344):216-226.
[2]
Bozic K J, Lau E, Chiu V, et al. The epidemiology of revision total knee arthroplasty in the United States[J]. ClinOrthopRelat Res,2010,468(1):45-51.
[13]
Porter J R, Ruckh T T, Popat K C. Bone tissue engineering: a review in bone biomimetics and drug delivery strategies[J].BiotechnolProg, 2009, 25(6):1539-1560.
[3]
Puckett S D, Taylor E, Raimondo T, et al. The relationship between the nanostructure of titanium surfaces and bacterial attachment[J]. Biomaterials,2010,31(4):706-713.
[14]
Wu P, Grainger D W. Drug/device combinations for local drug therapies and infection prophylaxis[J].Biomaterials,2006,27(11):2450-2467.
[4]
Hetrick E M, Schoenfsch M H. Reducing implant-related infections: active release strategies[J]. ChemSoc Rev,2006,35(9):780-789.
[15]
Liu H, Webster T J. Nanomedicine for implants: a review of studies and necessary experimental tools[J]. Biomaterials,2007,28(2):354-369.
[5]
Kurtz S M, Lau E, Schmier J, et al. Infection burden for hip and knee arthroplasty in the United States[J]. J Arthroplasty,2008,23(7):984-991.
[16]
Ghicov A, Schmuki P. Self-ordering electrochemistry: a review on growth and functionality of TiO2 nanotubes and other self-aligned MO(x) structures[J].ChemCommun(Camb),2009,(20):2791-2808.
[6]
Ribeiro M, Monteiro F J, Ferraz M P. Infection of orthopedic implants with emphasis on bacterial adhesion process and techniques used in studying bacterial-material interactions[J]. Biomatter,2012,2(4):176-194.
[17]
Losic D, Simovic S. Self-ordered nanopore and nanotube platforms for drug delivery applications[J]. Expert Opin Drug Deliv,2009,6(12): 1363-1381.
[7]
Costerton J W, Stewart P S, Greenberg E P. Bacterial bioflms: a common cause of persistent infections[J].Science, 1999,284(5418):1318-1322.
[18]
Gulati K, Aw M S, Losic D. Drug-eluting Ti wires with titania nanotube arrays for bone fxation and reduced bone infection[J]. Nanoscale Res Lett,2011,(6):571.
[8]
Davies D. Understanding bioflm resistance to antibacterial agents[J]. Nat Rev Drug Discov, 2003,2(2):114-122.
[9]
Popat K C, Eltgroth M, LaTempa T J, et al. Titania nanotubes: a novel platform for drug-eluting coatings for medical implants[J].Small,2007,3(11):1878-1881.
[19]
Popat K C, Eltgroth M, Latempa T J, et al. Decreased Staphylococcus Epidermis adhesion and increased osteoblast functional-ity on antibiotic-loaded titania nanotubes[J]. Biomaterials,2007,28(32): 4880-4888.
[10]
Diefenbeck M, Mückley T, Hofmann G O. Prophylaxis and treatment of implant-related infections by local application of antibiotics[J]. Injury,2006,37(2):95-104.
[20]
Wen taolin,hong lueTan,Zhaoling Duan,et al: Inhibited bacterial bioflm formation and improved osteogenic activity on gentamicin-loaded titania nanotubes with various diameters[J]. International Journal of Nanomedicine,2014,(9):1215-1230.
[21]
Neoh K G, Hu X, Zheng D, et al. Balancing osteoblast functions and bacterial adhesion on functionalized titanium surfaces[J].Biomaterials, 2012,33(10):2813-2822.
[11]
Gulati K, Aw M S, Findlay D, et al. Local drug delivery to the bone bydrug-releasing implants: perspectives of nano-engineered titania nanotube arrays[J].TherDeliv,2012,3(7):857-873.
[12]
Berger R A, Jacobs J J, Quigley L R, et al. Primary cementlessacetabular reconstruction in patients younger than 50 years old. 7- to 11-year results[J]. ClinOrthopRelat Res, 1997,(344):216-226.
[22]
Ercan B, Taylor E, Alpaslan E, et al. Diameter of titanium nanotubes influences anti-bacterial efficacy[J]. Nanotechnology,2011,22(29):292-295.
[23]
Arciola C R, Campoccia D, Speziale P, et al. Bioflm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for bioflm-resistant materials[J]. Biomaterials,2012,33(26):5967-5982.
[13]
Porter J R, Ruckh T T, Popat K C. Bone tissue engineering: a review in bone biomimetics and drug delivery strategies[J].BiotechnolProg, 2009, 25(6):1539-1560.
[24]
Soundrapandian C, Sa B, Datta S. Organic-inorganic composites for bone drug delivery[J]. AAPS Pharm Sci Tech, 2009,10(4):1158-1171.
[14]
Wu P, Grainger D W. Drug/device combinations for local drug therapies and infection prophylaxis[J].Biomaterials,2006,27(11):2450-2467.
[25]
Simchi A, Tamjid E, Pishbin F, et al. Recent progress in inorganic and composite coatings with bactericidal capability for orthopaedic applications[J].Nanomedicine,2011,7(1):22-39.
[15]
Liu H, Webster T J. Nanomedicine for implants: a review of studies and necessary experimental tools[J]. Biomaterials,2007,28(2):354-369.
[16]
Ghicov A, Schmuki P. Self-ordering electrochemistry: a review on growth and functionality of TiO2 nanotubes and other self-aligned MO(x) structures[J].ChemCommun(Camb),2009,(20):2791-2808.
[26]
Bjursten L M, Rasmusson L, Oh S, et al. Titanium dioxide nanotubes enhance bone bonding in vivo[J]. J Biomed Mater Res A,2010,92(3):1218-1224.
[27]
Arciola C R, Campoccia D, Gamberini S, et al. Antibiotic resistance in exopolysaccharide-forming Staphylococcus epidermidis clinical isolates from orthopaedic implant infections[J]. Biomaterials, 2005,26(33):6530-6535.
[17]
Losic D, Simovic S. Self-ordered nanopore and nanotube platforms for drug delivery applications[J]. Expert Opin Drug Deliv,2009,6(12): 1363-1381.
[28]
Rathbone C R, Cross J D, Brown K V, et al. Effect of various concentrations of antibiotics on osteogenic cell viability and activity[J]. J Orthop Res, 2011,29(7):1070-1074.
[18]
Gulati K, Aw M S, Losic D. Drug-eluting Ti wires with titania nanotube arrays for bone fxation and reduced bone infection[J]. Nanoscale Res Lett,2011,(6):571.
[19]
Popat K C, Eltgroth M, Latempa T J, et al. Decreased Staphylococcus Epidermis adhesion and increased osteoblast functional-ity on antibiotic-loaded titania nanotubes[J]. Biomaterials,2007,28(32): 4880-4888.
[20]
Wen taolin,hong lueTan,Zhaoling Duan,et al: Inhibited bacterial bioflm formation and improved osteogenic activity on gentamicin-loaded titania nanotubes with various diameters[J]. International Journal of Nanomedicine,2014,(9):1215-1230.
[21]
Neoh K G, Hu X, Zheng D, et al. Balancing osteoblast functions and bacterial adhesion on functionalized titanium surfaces[J].Biomaterials, 2012,33(10):2813-2822.
[22]
Ercan B, Taylor E, Alpaslan E, et al. Diameter of titanium nanotubes influences anti-bacterial efficacy[J]. Nanotechnology,2011,22(29):292-295.
[23]
Arciola C R, Campoccia D, Speziale P, et al. Bioflm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for bioflm-resistant materials[J]. Biomaterials,2012,33(26):5967-5982.
[24]
Soundrapandian C, Sa B, Datta S. Organic-inorganic composites for bone drug delivery[J]. AAPS Pharm Sci Tech, 2009,10(4):1158-1171.
[25]
Simchi A, Tamjid E, Pishbin F, et al. Recent progress in inorganic and composite coatings with bactericidal capability for orthopaedic applications[J].Nanomedicine,2011,7(1):22-39.
[26]
Bjursten L M, Rasmusson L, Oh S, et al. Titanium dioxide nanotubes enhance bone bonding in vivo[J]. J Biomed Mater Res A,2010,92(3):1218-1224.
[27]
Arciola C R, Campoccia D, Gamberini S, et al. Antibiotic resistance in exopolysaccharide-forming Staphylococcus epidermidis clinical isolates from orthopaedic implant infections[J]. Biomaterials, 2005,26(33):6530-6535.
[28]
Rathbone C R, Cross J D, Brown K V, et al. Effect of various concentrations of antibiotics on osteogenic cell viability and activity[J]. J Orthop Res, 2011,29(7):1070-1074.